Cinara Regina Aragão Vieira Monteiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cinara Regina Aragão Vieira Monteiro has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Valério Monteiro-Neto
Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, MA, Brazil
11 shared publications - Elizabeth Soares Fernandes
Department of Animal and Veterinary Sciences-ANIVET Ruminant Nutrition (RUN), Aarhus University, 8830 Tjele, Denmark
7 shared publications - Carmem Duarte Lima Campos
Postgraduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil
5 shared publications - José Lima Pereira Filho
Graduate Program in Health Sciences, Federal University of Maranhão (UFMA), São Luís 65080-805, Brazil
3 shared publications - Silvio Gomes Monteiro
Universidade Federal do Maranhão, Brasil
3 shared publications - Camilla Itapary dos Santos
Rede de Biodiversidade e Biotecnologia da Amazônia Legal, BIONORTE, São Luís 65055-310, MA, Brazil
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (7) , 1-20
Comprehensive Genomic Characterization and Probiotic Properties Evaluation of Limosilactobacillus fermentum JAC 231 Isolated from Vaginal Microbiota
Limosilactobacillus fermentum JAC 231, a strain isolated from the vaginal microbiota of an asymptomatic woman, was investigated for its genomic features, safety, probiotic potential, and antimicrobial properties in this study. Whole-genome sequencing revealed a 2.06 Mbp genome with 51.4% GC content and 1,993 predicted coding sequences (CDS). Functional annotation indicated that the genes were related to carbohydrate metabolism, stress tolerance, adhesion, and bacteriocin biosynthesis. Comparative analysis revealed that L. fermentum JAC 231 shared 1,587 orthologous groups with the other five probiotic strains of L. fermentum . No virulence factors or transferable antibiotic resistance genes were detected, and only an incomplete prophage region was identified, which supports the safety of this strain. Phenotypically, JAC 231 exhibited tolerance to acidic pH and bile salts and demonstrated high adhesion capacity to porcine gastric mucin (5.97 log₁₀ CFU/mL) and HeLa epithelial cells (5.79 log₁₀ CFU/mL). Antimicrobial susceptibility testing indicated resistance to vancomycin and moderate susceptibility to ciprofloxacin, features considered intrinsic and nontransferable. The strain exhibited broad-spectrum antimicrobial activity, with inhibition zones ranging from 16.60 ± 2.08 mm to 28.30 ± 2.88 mm against various Gram-positive and Gram-negative pathogens. Agar diffusion assays indicated that the antimicrobial activity of the cell-free supernatant was primarily due to the production of organic acids. Furthermore, JAC 231 significantly reduced pathogen adherence to epithelial cells in competitive, exclusion, and displacement assays. Collectively, these genomic and functional attributes support the safety and probiotic potential of L. fermentum JAC 231 and underscore its promise as a candidate for therapeutic applications targeting the urogenital and gastrointestinal microbiota.
- 28 April 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (7) , 1-20
Open AccessComprehensive Genomic Characterization and Probiotic Properties Evaluation of Limosilactobacillus fermentum JAC 231 Isolated from Vaginal Microbiota
Limosilactobacillus fermentum JAC 231, a strain isolated from the vaginal microbiota of an asymptomatic woman, was investigated for its genomic features, safety, probiotic potential, and antimicrobial properties in this study. Whole-genome sequencing revealed a 2.06 Mbp genome with 51.4% GC content and 1,993 predicted coding sequences (CDS). Functional annotation indicated that the genes were related to carbohydrate metabolism, stress tolerance, adhesion, and bacteriocin biosynthesis. Comparative analysis revealed that L. fermentum JAC 231 shared 1,587 orthologous groups with the other five probiotic strains of L. fermentum . No virulence factors or transferable antibiotic resistance genes were detected, and only an incomplete prophage region was identified, which supports the safety of this strain. Phenotypically, JAC 231 exhibited tolerance to acidic pH and bile salts and demonstrated high adhesion capacity to porcine gastric mucin (5.97 log₁₀ CFU/mL) and HeLa epithelial cells (5.79 log₁₀ CFU/mL). Antimicrobial susceptibility testing indicated resistance to vancomycin and moderate susceptibility to ciprofloxacin, features considered intrinsic and nontransferable. The strain exhibited broad-spectrum antimicrobial activity, with inhibition zones ranging from 16.60 ± 2.08 mm to 28.30 ± 2.88 mm against various Gram-positive and Gram-negative pathogens. Agar diffusion assays indicated that the antimicrobial activity of the cell-free supernatant was primarily due to the production of organic acids. Furthermore, JAC 231 significantly reduced pathogen adherence to epithelial cells in competitive, exclusion, and displacement assays. Collectively, these genomic and functional attributes support the safety and probiotic potential of L. fermentum JAC 231 and underscore its promise as a candidate for therapeutic applications targeting the urogenital and gastrointestinal microbiota.
- Top Cited PapersOpen Access
Prebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions
Background/Objectives: Prebiotics, which are non-digestible compounds that selectively modulate gut microbiota, are recognized for their potential to promote host health. Although their bifidogenic effect is well documented, a systematic synthesis of how this microbial modulation translates into clinical gastrointestinal (GI) and metabolic outcomes across diverse populations is needed. This review aims to integrate mechanistic insights with clinical evidence to elucidate the pathway from prebiotic structures to tangible health benefits. Methods: This comprehensive narrative review details the structural properties of major prebiotics (e.g., inulin, FOS, and GOS) that govern their fermentation and the production of short-chain fatty acids (SCFAs). To evaluate clinical efficacy, an analysis of 22 randomized controlled trials from the past decade was conducted, focusing on human studies that utilized ISAPP-recognized prebiotics as the sole intervention. Results: The analysis confirms that prebiotic supplementation consistently increased the abundance of beneficial bacteria (e.g., Bifidobacterium and Lactobacillus) and SCFA production. These changes are associated with significant clinical improvements, including enhanced stool frequency and consistency, strengthened intestinal barrier function, and modulated immune responses. Benefits have been documented in healthy individuals, children, the elderly, and those with conditions such as constipation, metabolic syndrome, and antibiotic-associated dysbiosis. However, significant inter-individual variability in response was evident, and the study designs showed notable heterogeneity in prebiotic type, dosage, and duration. Conclusions: Prebiotics are effective modulators of gut health, driving clinical benefits through selective microbial fermentation and SCFA production. The documented heterogeneity and variability highlight the need for future research to focus on personalized nutritional strategies. Key priorities include standardizing intervention protocols, elucidating dose–response relationships, integrating multi-omics data to link taxonomy to function, and exploring novel applications such as synbiotic formulations and gut–brain axis modulation.
Top Cited PapersOpen AccessPrebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions
Background/Objectives: Prebiotics, which are non-digestible compounds that selectively modulate gut microbiota, are recognized for their potential to promote host health. Although their bifidogenic effect is well documented, a systematic synthesis of how this microbial modulation translates into clinical gastrointestinal (GI) and metabolic outcomes across diverse populations is needed. This review aims to integrate mechanistic insights with clinical evidence to elucidate the pathway from prebiotic structures to tangible health benefits. Methods: This comprehensive narrative review details the structural properties of major prebiotics (e.g., inulin, FOS, and GOS) that govern their fermentation and the production of short-chain fatty acids (SCFAs). To evaluate clinical efficacy, an analysis of 22 randomized controlled trials from the past decade was conducted, focusing on human studies that utilized ISAPP-recognized prebiotics as the sole intervention. Results: The analysis confirms that prebiotic supplementation consistently increased the abundance of beneficial bacteria (e.g., Bifidobacterium and Lactobacillus) and SCFA production. These changes are associated with significant clinical improvements, including enhanced stool frequency and consistency, strengthened intestinal barrier function, and modulated immune responses. Benefits have been documented in healthy individuals, children, the elderly, and those with conditions such as constipation, metabolic syndrome, and antibiotic-associated dysbiosis. However, significant inter-individual variability in response was evident, and the study designs showed notable heterogeneity in prebiotic type, dosage, and duration. Conclusions: Prebiotics are effective modulators of gut health, driving clinical benefits through selective microbial fermentation and SCFA production. The documented heterogeneity and variability highlight the need for future research to focus on personalized nutritional strategies. Key priorities include standardizing intervention protocols, elucidating dose–response relationships, integrating multi-omics data to link taxonomy to function, and exploring novel applications such as synbiotic formulations and gut–brain axis modulation.
- Open Access
- 17 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1163
Antimicrobial and Anti-Infective Activity of Natural Products: Unveiling Mechanisms, Synergies, and Translational Applications
Antimicrobial resistance (AMR) is an urgent global challenge as microbial pathogens are increasingly developing resistance to traditional antibiotics
- 17 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1163
Open AccessAntimicrobial and Anti-Infective Activity of Natural Products: Unveiling Mechanisms, Synergies, and Translational Applications
Antimicrobial resistance (AMR) is an urgent global challenge as microbial pathogens are increasingly developing resistance to traditional antibiotics
- Open Access
- 23 January 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 171
Chikungunya Particle and RNA Induce Mechanical and Heat Hypersensitivities in a TRPV1-Dependent Manner
Chikungunya virus (CHIKV), the causative agent of the chikungunya fever, is an alphavirus widely transmitted by the bite of the female mosquito of the genus Aedes sp., especially in tropical and subtropical regions. Brazil is the country most affected by the microorganism. CHIKV classically induces articular pain, which can become long lasting for even years in a great number of the infected individuals, reducing their quality of life. The mechanisms of CHIKV-induced pain are poorly understood, but recent evidence indicated a role for the transient receptor potential vanilloid 1 (TRPV1) in this pathology. Herein, we assessed the ability of intra-articularly injected inactivated CHIKV or its RNA to trigger nociception in mice. Both stimuli induced bilateral secondary hyperalgesia to mechanical and heat stimuli. These responses were attenuated by TRPV1 ablation or antagonism. Joint structural alterations and increased cartilage TRPV1 protein expression were detected in the ipsilateral knee joints injected with either CHIKV or viral RNA. However, the lack of this receptor did not influence the histological changes triggered by CHIKV or RNA. The results further support the role of TRPV1 in CHIKV-induced pain and highlight its importance in the chronic phase of the disease.
- 23 January 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 171
Open AccessChikungunya Particle and RNA Induce Mechanical and Heat Hypersensitivities in a TRPV1-Dependent Manner
Chikungunya virus (CHIKV), the causative agent of the chikungunya fever, is an alphavirus widely transmitted by the bite of the female mosquito of the genus Aedes sp., especially in tropical and subtropical regions. Brazil is the country most affected by the microorganism. CHIKV classically induces articular pain, which can become long lasting for even years in a great number of the infected individuals, reducing their quality of life. The mechanisms of CHIKV-induced pain are poorly understood, but recent evidence indicated a role for the transient receptor potential vanilloid 1 (TRPV1) in this pathology. Herein, we assessed the ability of intra-articularly injected inactivated CHIKV or its RNA to trigger nociception in mice. Both stimuli induced bilateral secondary hyperalgesia to mechanical and heat stimuli. These responses were attenuated by TRPV1 ablation or antagonism. Joint structural alterations and increased cartilage TRPV1 protein expression were detected in the ipsilateral knee joints injected with either CHIKV or viral RNA. However, the lack of this receptor did not influence the histological changes triggered by CHIKV or RNA. The results further support the role of TRPV1 in CHIKV-induced pain and highlight its importance in the chronic phase of the disease.
- Open Access
- 15 November 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1091
A Comprehensive Review on the Antibacterial, Antifungal, Antiviral, and Antiparasitic Potential of Silybin
Silybin, a flavonolignan extracted from the seeds of the plant species Silybum marianum (L.) Gaertn., has a variety of pharmacological activities, including antimicrobial activity against several microorganisms of clinical interest. This review analyzes the existing studies on silybin’s antimicrobial activity and possible mechanisms of action. Silybin has been shown to inhibit the growth of Gram-positive and Gram-negative bacteria, as well as some fungi, viruses, and protozoa. In general, possible mechanisms of antimicrobial action include the inhibition of efflux pumps, prevention of biofilm formation, reduction of the expression of virulence factors, induction of apoptosis-like effects, and plasma membrane damage, as well as the inhibition of nucleic acid and protein synthesis. Silybin has been shown to have synergistic effects when combined with conventional antibiotics against both drug-sensitive and drug-resistant microorganisms. However, the low bioavailability observed for this flavonolignan has been a challenge to its clinical use. In this context, nanotechnology has been used to increase silybin’s bioavailability while enhancing its antimicrobial activity. Furthermore, certain structural modifications have been able to enhance its antimicrobial activity in comparison to that of the natural molecule. Overall, this review provides insights into the scientific understanding of the mechanism of action of silybin and its desired properties for the effective treatment of infections.
- 15 November 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1091
Open AccessA Comprehensive Review on the Antibacterial, Antifungal, Antiviral, and Antiparasitic Potential of Silybin
Silybin, a flavonolignan extracted from the seeds of the plant species Silybum marianum (L.) Gaertn., has a variety of pharmacological activities, including antimicrobial activity against several microorganisms of clinical interest. This review analyzes the existing studies on silybin’s antimicrobial activity and possible mechanisms of action. Silybin has been shown to inhibit the growth of Gram-positive and Gram-negative bacteria, as well as some fungi, viruses, and protozoa. In general, possible mechanisms of antimicrobial action include the inhibition of efflux pumps, prevention of biofilm formation, reduction of the expression of virulence factors, induction of apoptosis-like effects, and plasma membrane damage, as well as the inhibition of nucleic acid and protein synthesis. Silybin has been shown to have synergistic effects when combined with conventional antibiotics against both drug-sensitive and drug-resistant microorganisms. However, the low bioavailability observed for this flavonolignan has been a challenge to its clinical use. In this context, nanotechnology has been used to increase silybin’s bioavailability while enhancing its antimicrobial activity. Furthermore, certain structural modifications have been able to enhance its antimicrobial activity in comparison to that of the natural molecule. Overall, this review provides insights into the scientific understanding of the mechanism of action of silybin and its desired properties for the effective treatment of infections.
- Open Access
- 15 June 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (6) , 1051
Antimicrobial and Anti-Infective Activity of Natural Products—Gaining Knowledge from Novel Studies
Despite advances in the development of antimicrobial drugs in the last centuries, antimicrobial resistance has consistently raised in the last decades, compromising their effectiveness. Novel antimicrobial compounds, especially from natural sources, including plants, microorganisms, and animals, have since become a growing area of research. In this context, studies covering the investigation of their ability to combat resistant microorganisms, either by neutralization or inactivation of pathogen resistance mechanisms and virulence properties, have gained attention. Herein, a collection of 19 manuscripts focused on the antimicrobial and anti-infective activity of natural products, including their mechanisms of action, in silico evidence of antimicrobial activity, synergistic associations with antibiotics, and other aspects, will be discussed.
- 15 June 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (6) , 1051
Open AccessAntimicrobial and Anti-Infective Activity of Natural Products—Gaining Knowledge from Novel Studies
Despite advances in the development of antimicrobial drugs in the last centuries, antimicrobial resistance has consistently raised in the last decades, compromising their effectiveness. Novel antimicrobial compounds, especially from natural sources, including plants, microorganisms, and animals, have since become a growing area of research. In this context, studies covering the investigation of their ability to combat resistant microorganisms, either by neutralization or inactivation of pathogen resistance mechanisms and virulence properties, have gained attention. Herein, a collection of 19 manuscripts focused on the antimicrobial and anti-infective activity of natural products, including their mechanisms of action, in silico evidence of antimicrobial activity, synergistic associations with antibiotics, and other aspects, will be discussed.
- Open Access
- 19 December 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (12) , 1842
In Silico and In Vitro Analysis of Sulforaphane Anti-Candida Activity
Oropharyngeal candidiasis/candidosis is a common and recurrent opportunistic fungal infection. Fluconazole (FLZ), one of the most used and effective antifungal agents, has been associated with a rise of resistant Candida species in immunocompromised patients undergoing prophylactic therapy. Sulforaphane (SFN), a compound from cruciferous vegetables, is an antimicrobial with yet controversial activities and mechanisms on fungi. Herein, the in silico and antifungal activities of SFN against C. albicans were investigated. In silico analyzes for the prediction of the biological activities and oral bioavailability of SFN, its possible toxicity and pharmacokinetic parameters, as well as the estimates of its gastrointestinal absorption, permeability to the blood-brain barrier and skin, and similarities to drugs, were performed by using different software. SFN in vitro anti-Candida activities alone and in combination with fluconazole (FLZ) were determined by the broth microdilution method and the checkerboard, biofilm and hyphae formation tests. Amongst the identified probable biological activities of SFN, nine indicated an antimicrobial potential. SFN was predicted to be highly absorbable by the gastrointestinal tract, to present good oral availability, and not to be irritant and/or hepatotoxic. SFN presented antifungal activity against C. albicans and prevented both biofilm and hyphae formation by this microorganism. SFN was additive/synergistic to FLZ. Overall, the data highlights the anti-Candida activity of SFN and its potential to be used as an adjuvant therapy to FLZ in clinical settings.
- 19 December 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (12) , 1842
Open AccessIn Silico and In Vitro Analysis of Sulforaphane Anti-Candida Activity
Oropharyngeal candidiasis/candidosis is a common and recurrent opportunistic fungal infection. Fluconazole (FLZ), one of the most used and effective antifungal agents, has been associated with a rise of resistant Candida species in immunocompromised patients undergoing prophylactic therapy. Sulforaphane (SFN), a compound from cruciferous vegetables, is an antimicrobial with yet controversial activities and mechanisms on fungi. Herein, the in silico and antifungal activities of SFN against C. albicans were investigated. In silico analyzes for the prediction of the biological activities and oral bioavailability of SFN, its possible toxicity and pharmacokinetic parameters, as well as the estimates of its gastrointestinal absorption, permeability to the blood-brain barrier and skin, and similarities to drugs, were performed by using different software. SFN in vitro anti-Candida activities alone and in combination with fluconazole (FLZ) were determined by the broth microdilution method and the checkerboard, biofilm and hyphae formation tests. Amongst the identified probable biological activities of SFN, nine indicated an antimicrobial potential. SFN was predicted to be highly absorbable by the gastrointestinal tract, to present good oral availability, and not to be irritant and/or hepatotoxic. SFN presented antifungal activity against C. albicans and prevented both biofilm and hyphae formation by this microorganism. SFN was additive/synergistic to FLZ. Overall, the data highlights the anti-Candida activity of SFN and its potential to be used as an adjuvant therapy to FLZ in clinical settings.
- Open Access
- 24 September 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (10) , 794
Genomic Analysis of Limosilactobacillus fermentum ATCC 23271, a Potential Probiotic Strain with Anti-Candida Activity
Limosilactobacillus fermentum (ATCC 23271) was originally isolated from the human intestine and has displayed antimicrobial activity, primarily against Candida species. Complete genome sequencing and comparative analyses were performed to elucidate the genetic basis underlying its probiotic potential. The ATCC 23271 genome was found to contain 2,193,335 bp, with 2123 protein-coding sequences. Phylogenetic analysis revealed that the ATCC 23271 strain shares 941 gene clusters with six other probiotic strains of L. fermentum. Putative genes known to confer probiotic properties have been identified in the genome, including genes related to adhesion, tolerance to acidic pH and bile salts, tolerance to oxidative stress, and metabolism and transport of sugars and other compounds. A search for bacteriocin genes revealed a sequence 48% similar to that of enterolysin A, a protein from Enterococcus faecalis. However, in vitro assays confirmed that the strain has inhibitory activity on the growth of Candida species and also interferes with their adhesion to HeLa cells. In silico analyses demonstrated a high probability of the protein with antimicrobial activity. Our data reveal the genome features of L. fermentum ATCC 23271, which may provide insight into its future use given the functional benefits, especially against Candida infections.
- 24 September 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (10) , 794
Open AccessGenomic Analysis of Limosilactobacillus fermentum ATCC 23271, a Potential Probiotic Strain with Anti-Candida Activity
Limosilactobacillus fermentum (ATCC 23271) was originally isolated from the human intestine and has displayed antimicrobial activity, primarily against Candida species. Complete genome sequencing and comparative analyses were performed to elucidate the genetic basis underlying its probiotic potential. The ATCC 23271 genome was found to contain 2,193,335 bp, with 2123 protein-coding sequences. Phylogenetic analysis revealed that the ATCC 23271 strain shares 941 gene clusters with six other probiotic strains of L. fermentum. Putative genes known to confer probiotic properties have been identified in the genome, including genes related to adhesion, tolerance to acidic pH and bile salts, tolerance to oxidative stress, and metabolism and transport of sugars and other compounds. A search for bacteriocin genes revealed a sequence 48% similar to that of enterolysin A, a protein from Enterococcus faecalis. However, in vitro assays confirmed that the strain has inhibitory activity on the growth of Candida species and also interferes with their adhesion to HeLa cells. In silico analyses demonstrated a high probability of the protein with antimicrobial activity. Our data reveal the genome features of L. fermentum ATCC 23271, which may provide insight into its future use given the functional benefits, especially against Candida infections.
- Open Access
In Vitro Antimicrobial Activity and Probiotic Potential of Bifidobacterium and Lactobacillus against Species of Clostridium
Many Clostridium species are found as commensal members of the intestinal microbiota. However, imbalances of the microbiota may lead to certain infections caused by these microorganisms, mainly Clostridium butyricum, Clostridium difficile, and Clostridium perfringens. In many cases, infection recurrence can occur after antibiotics, indicating the need for novel therapeutic options that act on the pathogens and also restore the microbiota. Herein, the in vitro antimicrobial activity and probiotic potential of clinical and reference strains of Bifidobacterium and Lactobacillus were investigated against Clostridium species. Antimicrobial activity was evaluated by the agar spot test and inhibition of gas production. Then, the probiotic potential of selected strains was assessed by analyzing their coaggregation ability, adhesive properties to host cells and mucin, tolerance to acidic pH and bile salts, and antimicrobial susceptibility profiles. Lactobacillus plantarum ATCC 8014 was the most promising strain based on its inhibitory activity against Clostridium spp. Also, this strain met criteria to be considered a probiotic based on its coaggregation ability, adhesive properties, and tolerance to harsh pH and bile acid salt conditions. The results indicate that among the studied strains, L. plantarum ATCC 8014 presents probiotic potential for controlling infections induced by the studied Clostridium species and should be further evaluated in in vivo animal models.
Open AccessIn Vitro Antimicrobial Activity and Probiotic Potential of Bifidobacterium and Lactobacillus against Species of Clostridium
Many Clostridium species are found as commensal members of the intestinal microbiota. However, imbalances of the microbiota may lead to certain infections caused by these microorganisms, mainly Clostridium butyricum, Clostridium difficile, and Clostridium perfringens. In many cases, infection recurrence can occur after antibiotics, indicating the need for novel therapeutic options that act on the pathogens and also restore the microbiota. Herein, the in vitro antimicrobial activity and probiotic potential of clinical and reference strains of Bifidobacterium and Lactobacillus were investigated against Clostridium species. Antimicrobial activity was evaluated by the agar spot test and inhibition of gas production. Then, the probiotic potential of selected strains was assessed by analyzing their coaggregation ability, adhesive properties to host cells and mucin, tolerance to acidic pH and bile salts, and antimicrobial susceptibility profiles. Lactobacillus plantarum ATCC 8014 was the most promising strain based on its inhibitory activity against Clostridium spp. Also, this strain met criteria to be considered a probiotic based on its coaggregation ability, adhesive properties, and tolerance to harsh pH and bile acid salt conditions. The results indicate that among the studied strains, L. plantarum ATCC 8014 presents probiotic potential for controlling infections induced by the studied Clostridium species and should be further evaluated in in vivo animal models.
- Open Access
- 20 December 2017
- Published by IntechOpen
Microbiology of Ventilator-Associated Pneumonia
Ventilator-associated pneumonia (VAP) is a pulmonary infection that appears after 2 days of endotracheal intubation and when invasive mechanical ventilation is used. VAP is considered the most common nosocomial infection in the intensive care unit (ICU) and presents high morbidity and mortality rates, principally when caused by multi-resistant bacteria. Several risk factors are associated with VAP, including the microbiota, advanced age, immunocompromising conditions, pulmonary illness, length of mechanical ventilation, the aspiration technique, tracheostomy, supine positioning, enteral feeding, previous antibiotic exposure, among other endogenous and exogenous factors. The main pathogens are Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae members, which are considered potentially multidrug-resistant pathogens. Conventional microbiology methods continue to be used for laboratory diagnosis. However, it is necessary to validate rapid and accurate laboratory methods, such as molecular assays that detect multiple gene sequences of a wide range of bacterial species and resistance markers. Therefore, the objective of this chapter is to review and update several aspects related to VAP, including risk factors, etiology, laboratory diagnosis, bacterial virulence and VAP severity, and antibiotic susceptibility.
- 20 December 2017
- Published by IntechOpen
Open AccessMicrobiology of Ventilator-Associated Pneumonia
Ventilator-associated pneumonia (VAP) is a pulmonary infection that appears after 2 days of endotracheal intubation and when invasive mechanical ventilation is used. VAP is considered the most common nosocomial infection in the intensive care unit (ICU) and presents high morbidity and mortality rates, principally when caused by multi-resistant bacteria. Several risk factors are associated with VAP, including the microbiota, advanced age, immunocompromising conditions, pulmonary illness, length of mechanical ventilation, the aspiration technique, tracheostomy, supine positioning, enteral feeding, previous antibiotic exposure, among other endogenous and exogenous factors. The main pathogens are Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae members, which are considered potentially multidrug-resistant pathogens. Conventional microbiology methods continue to be used for laboratory diagnosis. However, it is necessary to validate rapid and accurate laboratory methods, such as molecular assays that detect multiple gene sequences of a wide range of bacterial species and resistance markers. Therefore, the objective of this chapter is to review and update several aspects related to VAP, including risk factors, etiology, laboratory diagnosis, bacterial virulence and VAP severity, and antibiotic susceptibility.